Eli Lilly and Company (NYSE:LLY) Trading 1.4% Higher – Here’s Why

19 Dec 2025, 22:46 by Sarita Garza · The Markets Daily

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price was up 1.4% during mid-day trading on Friday . The stock traded as high as $1,075.38 and last traded at $1,071.35. Approximately 5,749,879 shares were traded during trading, an increase of 42% from the average daily volume of 4,035,005 shares. The stock had previously closed at $1,056.88.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Orforglipron hit its primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial — patients who switched from Wegovy or Zepbound maintained virtually all prior weight loss; Lilly has filed orforglipron with the FDA for obesity, paving the way for a potential oral alternative to injectables. Lilly PR: Orforglipron Phase 3
Positive Sentiment: Major outlets reported the trial results and FDA filing, which materially raises the odds Lilly can capture market share from injectable GLP‑1s — an investor-friendly growth thesis if approved and reimbursed. CNBC: Lilly pill maintains weight loss
Positive Sentiment: Chugai and other partners highlighted positive Phase 3 topline data and Lilly’s FDA filing, reinforcing confidence in regulatory and commercial execution for the oral program. TipRanks: Chugai update on orforglipron
Positive Sentiment: Bank of America / sell‑side commentary lifted quality/valuation views and flagged material upside tied to oral obesity drug sales (BofA sees multi‑billion dollar potential). That analyst optimism supports near‑term multiple expansion. Benzinga: BofA bullish on Lilly
Positive Sentiment: Street upgrades continue — Daiwa raised its view on LLY, adding to momentum from bullish coverage and positive earnings/guidance execution. American Banking News: Daiwa upgrade
Neutral Sentiment: Lilly is advancing other obesity/diabetes assets (e.g., eloralintide into Phase 3), which diversifies long‑term growth but is less likely to move near‑term results. TipRanks: Eloralintide Phase 3
Neutral Sentiment: Marketing and brand initiatives (e.g., Olympic partnerships) support awareness but have limited immediate financial impact relative to clinical/regulatory news. MMM‑Online: Olympics marketing
Negative Sentiment: Reuters reported Lilly cut list prices for Mounjaro and Zepbound in Canada by ~20%+, which could pressure revenue per patient in that market and signals payer pricing leverage — a potential headwind if similar moves spread. Reuters: Price cuts in Canada

Analysts Set New Price Targets

A number of equities research analysts recently commented on LLY shares. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,141.73.

Read Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Price Performance

The firm has a market cap of $1.01 trillion, a PE ratio of 52.41, a P/E/G ratio of 1.31 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business’s fifty day moving average is $956.00 and its 200-day moving average is $828.10.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the company earned $1.18 earnings per share. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently made changes to their positions in LLY. Finivi Inc. grew its stake in shares of Eli Lilly and Company by 2.0% during the 3rd quarter. Finivi Inc. now owns 4,920 shares of the company’s stock worth $3,754,000 after acquiring an additional 95 shares during the period. AIA Group Ltd raised its stake in Eli Lilly and Company by 34.9% in the 3rd quarter. AIA Group Ltd now owns 46,963 shares of the company’s stock valued at $35,833,000 after acquiring an additional 12,150 shares during the period. Keel Point LLC lifted its holdings in Eli Lilly and Company by 0.6% during the third quarter. Keel Point LLC now owns 3,609 shares of the company’s stock valued at $2,753,000 after purchasing an additional 21 shares during the last quarter. Garde Capital Inc. boosted its position in Eli Lilly and Company by 1.7% during the third quarter. Garde Capital Inc. now owns 1,632 shares of the company’s stock worth $1,245,000 after purchasing an additional 28 shares during the period. Finally, Bourne Lent Asset Management Inc. boosted its position in Eli Lilly and Company by 0.4% during the third quarter. Bourne Lent Asset Management Inc. now owns 3,922 shares of the company’s stock worth $2,992,000 after purchasing an additional 15 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.